GlassScriptPhysician profile
Michael R Macdonald
NPI 1427196625
$8,611.82
in general payments reported to CMS, 2019-2025
11 companies · $963 in 2025
The $963 reported for 2025 was more than what 85% of Facial Plastic Surgery providers received nationally (typical 2025 total: $271).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,719 · 2020: $1,643 · 2021: $594 · 2022: $765 · 2023: $557 · 2024: $2,370 · 2025: $963.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,368 · Travel and Lodging: $1,522.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,368.31 |
| Travel and Lodging | $1,522.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $5,608.49 | 2019-2025 | Scopis Ent, Audion Et Dilation System, Xpress Ent Dilation System |
| Integra Lifesciences Corporation | $1,171.61 | 2024 | Inspira Air, Acclarent Aera, Relieva Spinplus Nav |
| Glaxosmithkline, LLC. | $356.45 | 2022-2025 | Nucala |
| Revance Therapeutics, INC. | $341.47 | 2024-2025 | Daxxify |
| Galderma Laboratories, L.P. | $296.00 | 2019-2020 | |
| Optinose US, INC. | $271.63 | 2019 | |
| Inspire Medical Systems, INC. | $257.01 | 2023-2024 | Inspire |
| Abbvie INC. | $202.37 | 2022 | |
| Intersect Ent, INC. | $59.42 | 2020 | |
| Vertex Pharmaceuticals Incorporated | $29.92 | 2025 | |
| Bausch & Lomb Americas INC. | $17.45 | 2024 | Xiidra, Miebo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Macdonald listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.